Navigation Links
Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
Date:7/30/2009

BEIJING, July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received notice of patent pending from the State Intellectual Property Office of the People's Republic of China for its innovative patent application of Gliclazide-Controlled Release Tablets submitted in 2008. Meanwhile, Gliclazide-Controlled Release Tablets has undergone pre-clinical evaluation approved by the State Food and Drug Administration in 2009.

Gliclazide-Controlled Release Tablets is a modified controlled-release antidiabetic drug to treat type 2 diabetes. The market size of diabetes drugs is estimated to be approximately $1 billion in China(1) and the Company believes it will continue to grow as living standards have improved. "We have made additional investment to develop a controlled-release version of a product and our R&D team is knowledgeable in controlled delivery for potential and approved new pharmaceuticals," said Chairman and CEO of Lotus Dr. Liu. "For the development of our product portfolios, we emphasize on the applying of controlled-release technologies in the preclinical development of drugs to maximize market exposure. We believe formulations of this particular innovation may potentially offer greater effectiveness in the treatment of diabetes by minimizing impacts from gastric acid, and reduced side-effects by minimizing peak plasma concentrations."

    (1) Source: CHINA ANTI-DIABETIC DRUG MARKET REPORT prepared by Life
        Science Intelligence

About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs a
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
2. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
3. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
4. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
5. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
6. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
11. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeuti...tient in a randomized Phase 2B study of AEG35156, ...lopment for multiple oncology indications. ,, T... 2 Study of the X-Linked Inhibitor of Apoptosis (X...High-dose Cytarabine and Idarubicin in AML Followi...
(Date:11/18/2009)...AVIS, Calif., Nov. 18 Marrone Bio ...lopment and commercialization of effective and env... announced that it has been named an IC20 company ...t and largest national angel investing group. ,... leading to rewarding results for all stakeholders...
(Date:11/18/2009)... RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ ...unced today that data from the University of Penns...y of Sangamo,s zinc finger nuclease (ZFN) based pr...nd prematurely disclosed on the internet. ,, Da...rsity of Pennsylvania School of Medicine from a si...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
... Even with layoff announcements...employment continued to increase in September, gai...th it seemed like no one was searching for those n...ocus) October 31, 2008 -- Strong growth continues ...0 jobs created each month. Even with layoff announ...
...GO, Oct. 30 Accumetrics, Inc. has appointed,Timot...ecutive Officer. Mr.,Still has been serving in the... for the company since earlier this year., "Tim h...and startup,experience for our Board," says Tony A... Executive Chairman of the Board at Accumetrics. "...
...GE, Mass., Oct. 30 Idenix,Pharmaceuticals, Inc. (...ed,in the discovery and development of drugs for t...iseases, today reported unaudited financial result...ember 30, 2008. At,September 30, 2008, Idenix,s ca...aled approximately $60.1 million., 2008 Year-to-D...
Other Biology Technology:The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3Timothy I. Still Appointed CEO at Accumetrics 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 5Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 6Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 7
(Date:11/19/2009)...ISON This week, scientists are revealing the gene... cereal crops. Corn, or maize, has one of the most...ersity of Wisconsin-Madison genomicist David Schwa...rticle in the journal Science . , "The maize ge... dead-ends that have troubled would-be sequencers ...
(Date:11/19/2009)... , WALL, N.J., Nov. 19 /PRNewswire-FirstCal...ard: BKYI), a leader in wireless public safety and...announced that the Special Shareholder Meeting hel...en because a quorum was not present. ,, (Logo: ...EYLOGO) ,, While an impressive 99.3% of the 35 ...
(Date:11/19/2009)...ACA, N.Y. - A new study of maize has identified th...le portions of the genome. New techniques may allo...iation to identify desirable traits and create new..., Publishing in the Nov. 19 issue of Science , t...at Cornell, have identified the first map of haplo...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New map of variation in maize genetics holds promise for developing new varieties 2Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 12482 1Bart Peterson to Join Lilly Leadership Team 48032 1Bart Peterson to Join Lilly Leadership Team 48032 2Bart Peterson to Join Lilly Leadership Team 48032 3Akaza Research to Present and Exhibit at Upcoming DIA Annual Meeting 12481 1Akaza Research to Present and Exhibit at Upcoming DIA Annual Meeting 12481 2
...p revolutionary drug delivery methods that are mor...ions of patients. , Chemists at The University of... drugs in plastics, using methods that do not dama...ical drugs which are at the cutting edge of modern...ting drugs can use high temperatures and harsh sol...
...ional (CI) today announced a partnership with Toyo...than 4,000 acres of the Philippines Peablanca Prot...e Northeastern part of one of the nations main isl...l communities will receive additional benefits fro...ment. , The site was chosen to launch the partner...
...he Neanderthals died out because of competition wi...tic conditions. Although scientists have gained in...icult to pinpoint the climatic character at the ti...y an international team of researchers, published ...eveloped a breakthrough approach to address this i...
Other Biology News:Using green chemistry to deliver cutting-edge drugs 2Using green chemistry to deliver cutting-edge drugs 3Using green chemistry to deliver cutting-edge drugs 4Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2
...nterferons are cytopathic effect inhibition assays...types include; tissue culture supernatents; serum ...se assays, one unit is defined as the quantity of ...ytopathic effect of viral infection by 50%. All ...
Guanylyltransferase (5 U/l) from Ambion
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
Biology Products: